Evaluating the effectiveness of reformulated extended-release oxycodone with abuse-deterrent properties on reducing non-oral abuse among individuals assessed for substance abuse treatment with the Addiction Severity Index-Multimedia Version (ASI-MV)

References

• OxyContin (oxycodone hydrochloride) Extended-Release Tablets. Full prescribing information. Purdue Pharma L.P; [accessed 2022 Aug 2]. Available from: http://app.purduepharma.com/xmlpublishing/pi.aspx?id=o
   Google Scholar
• Hays LR. A profile of OxyContin addiction. J Addict Dis. 2004;23(4):1–9.
   PubMed Web of Science ®Google Scholar
• Sees KL, Di Marino ME, Ruediger NK, et al. Non-medical use of OxyContin tablets in the United States. J Pain Palliat Care Pharmacother. 2005;19:13–23.
   PubMedGoogle Scholar
• Pitt AL, Humphreys K, Brandeau ML. Modeling health benefits and harms of public policy responses to the US opioid epidemic. Am J Public Health. 2018;108(10):1394–1400.
   PubMed Web of Science ®Google Scholar
• Greene D. Total necrosis of the intranasal structures and soft palate as a result of nasal inhalation of crushed OxyContin. Ear Nose Throat J. 2005;84(8):512.
   PubMedGoogle Scholar
• Jewers WM, Rawal YB, Allen CM, et al. Palatal perforation associated with intranasal prescription narcotic abuse. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005;99(5):594–597.
   PubMed Web of Science ®Google Scholar
• Strang J, Bearn J, Farrell M, et al. Route of drug use and its implications for drug effect, risk of dependence and health consequences. Drug Alcohol Rev. 1998;17(2):197–211.
   PubMed Web of Science ®Google Scholar
• Yewell J, Haydon R, Archer S, et al. Complications of intranasal prescription narcotic abuse. Ann Otol Rhinol Laryngol. 2002;111(2):174–177.
   PubMed Web of Science ®Google Scholar
• Green JL, Bucher Bartelson B, Le Lait MC, et al. Medical outcomes associated with prescription opioid abuse via oral and non-oral routes of administration. Drug Alcohol Depend. 2017;175:140–145.
   PubMed Web of Science ®Google Scholar
• Perrino PJ, Colucci SV, Apseloff G, et al. Pharmacokinetics, tolerability, and safety of intranasal administration of reformulated OxyContin(®) tablets compared with original OxyContin (®) tablets in healthy adults. Clin Drug Investig. 2013;33(6):441–449.
   PubMed Web of Science ®Google Scholar
• Sellers EM, Perrino PJ, Colucci SV, et al. Attractiveness of reformulated OxyContin(R) tablets: assessing comparative preferences and tampering potential. J Psychopharmacol. 2013;27(9):808–816.
   PubMed Web of Science ®Google Scholar
• Harris SC, Perrino PJ, Smith I, et al. Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users. J Clin Pharmacol. 2014;54(4):468–477.
   PubMed Web of Science ®Google Scholar
• US Food & Drug Administration. 2020 Joint meeting of the drug safety and risk management advisory committee and the anesthetic and analgesic drug products advisory committee meeting announcement; 2020 Sept 10–11 [accessed 2022 Aug 2]. Available from: https://www.fda.gov/advisory-committees/advisory-committee-calendar/september-10-11-2020-joint-meeting-drug-safety-and-risk-management-advisory-committee-and-anesthetic
   Google Scholar
• US Food and Drug Administration. Abuse-deterrent opioids – evaluation and labeling. guidance for industry; 2015 April [accessed 2022 Aug 2]. Available from: https://www.fda.gov/media/84819/download
   Google Scholar
• US Food and Drug Administration. Abuse-deterrent opioid analgesics; 2021 [accessed 2023 Jan 20]. Available from: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/abuse-deterrent-opioid-analgesics
   Google Scholar
• Butler SF, Cassidy TA, Chilcoat H, et al. Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. J Pain. 2013;14(4):351–358.
   PubMed Web of Science ®Google Scholar
• Beachler DC, Hall K, Garg R, et al. An evaluation of the effect of the OxyContin reformulation on unintentional fatal and nonfatal overdose. Clin J Pain. 2022;38(6):396–404.
   PubMed Web of Science ®Google Scholar
• Roland CL, Setnik B, Brown DA. Assessing the impact of abuse-deterrent opioids (ADOs): identifying epidemiologic factors related to new entrants with low population exposure. Postgrad Med. 2017;129(1):12–21.
   PubMed Web of Science ®Google Scholar
• Secora AM, Dormitzer CM, Staffa JA, et al. Measures to quantify the abuse of prescription opioids: a review of data sources and metrics. Pharmacoepidemiol Drug Saf. 2014;23(12):1227–1237.
   PubMed Web of Science ®Google Scholar
• Butler SF, Budman SH, Licari A, et al. National addictions vigilance intervention and prevention program (NAVIPPRO): a real-time, product-specific, public health surveillance system for monitoring prescription drug abuse. Pharmacoepidemiol Drug Saf. 2008;17(12):1142–1154.
   PubMed Web of Science ®Google Scholar
• Butler SF, Budman SH, Goldman RJ, et al. Initial validation of a computer-administered addiction severity index: the ASI-MV. Psychol Addict Behav. 2001;15(1):4–12.
   PubMed Web of Science ®Google Scholar
• McLellan AT, Luborsky L, Cacciola J, et al. New data from the addiction severity index. J Nerv Ment Dis. 1985;173(7):412–423.
   PubMed Web of Science ®Google Scholar
• Butler SF, Villapiano A, Malinow A. The effect of computer-mediated administration on self-disclosure of problems on the addiction severity index. J Addict Med. 2009;3(4):194–203.
   PubMed Web of Science ®Google Scholar
• Dart RC, Iwanicki JL, Dasgupta N, et al. Do abuse deterrent opioid formulations work? J Opioid Manag. 2017;13(6):365–378.
   PubMedGoogle Scholar
• By K, McAninch JK, Keeton SL, et al. Important statistical considerations in the evaluation of post-market studies to assess whether opioids with abuse-deterrent properties result in reduced abuse in the community. Pharmacoepidemiol Drug Saf. 2018;27(5):473–478.
   PubMed Web of Science ®Google Scholar
• US Food & Drug Administration. Joint meeting of the drug safety and risk management advisory committee and the anesthetic and analgesic drug products advisory committee. FDA briefing document. Oxycontin abuse deterrent formulation (ADF); 2020 Sept 10–11 [accessed 2022 Aug 2]. Available from: https://www.fda.gov/media/141914/download
   Google Scholar